Furthermore, a proportion of human lung adenocarcinoma patients exhibit antibodies against HERV‐K Env, and increased levels of these antibodies following immune checkpoint blockade therapy are positively correlated with patient survival (Ng et al. 2023). Here, ERVW-1 is linked to lung adenocarcinoma.